Every material Form 8-K INOVIO PHARMACEUTICALS, INC. has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 5, 2026, Inovio agreed to sell 58,747,235 common shares at $1.05 each and pre-funded warrants for 12,681,337 shares at $1.049 each, and on November 6 the underwriters exercised their option to buy 10,714,285 more shares in full. Net proceeds are expected to be about $80.5 million, with closing expected on or about November 9, 2026. The sale adds to the shares outstanding, which dilutes existing holders, but the company says the proceeds and current cash will fund operations into late fourth quarter 2027.
58,747,235 common shares sold at $1.05 per share, plus pre-funded warrants for 12,681,337 shares at $1.049 each
Underwriters exercised their option for 10,714,285 additional shares in full on November 6, 2026
Net proceeds expected to be about $80.5 million; closing expected on or about November 9, 2026
Company believes proceeds and current cash will fund operations into late fourth quarter 2027
Inovio Pharmaceuticals disclosed a preliminary, unaudited estimate that its cash, cash equivalents and short-term investments were about $48.4 million as of September 30, 2026. The company says the figure is not a full quarterly result, is subject to closing procedures, and has not been audited or reviewed by Ernst & Young LLP, and actual results may differ materially.
Preliminary cash, cash equivalents and short-term investments: approximately $48.4 million as of September 30, 2026
Figure is based on unaudited information and management estimates for the quarter ended September 30, 2026
Ernst & Young LLP has not audited, reviewed or provided assurance on the preliminary data
Filing was signed by CFO Peter Kies on November 5, 2026
INOVIO announced on October 30, 2026 that the FDA granted accelerated approval for VOCERYQ, a DNA-based immunotherapy, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). The company expects to make the product available to order and ship in about 60 days and to deploy its full field team in the first quarter of 2027, and it must submit a draft confirmatory study protocol by the end of 2026. The filing does not disclose revenue, pricing, or financial projections, so the near-term financial effect on shareholders is not quantified.
FDA granted accelerated approval on October 30, 2026 for VOCERYQ in combination with the CELLECTRA 5PSP delivery device
In the efficacy population of 26 patients, 7 (27%) had a complete response after 12 months of follow-up, based on the RRP-001 study
Order-and-ship availability expected in about 60 days; full field deployment expected in Q1 2027 with Syneos Health support
Continued approval may depend on a confirmatory study; draft protocol due by end of 2026 and final protocol expected by mid-2027
Inovio reported a second-quarter 2026 net loss of $6.0 million, or $0.07 per share, down from $23.5 million, or $0.61 per share, a year earlier. The company said the decline was driven mainly by a $13.9 million non-cash gain on warrant liabilities, while operating expenses fell to $18.6 million from $23.1 million. Cash and short-term investments were $36.7 million at June 30, 2026, down from $58.5 million at December 31, 2025, before about $18.3 million in July offering proceeds.
Net loss of $6.0 million, or $0.07 per share, versus $23.5 million, or $0.61 per share, in Q2 2025
Non-cash warrant liability gain of $13.9 million; total operating expenses fell to $18.6 million from $23.1 million
Cash, cash equivalents and short-term investments of $36.7 million at June 30, 2026, excluding about $18.3 million in July offering proceeds
Cash expected to fund operations into late first quarter 2027, through a potential INO-3107 launch if approved; FDA PDUFA target date is October 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every INOVIO PHARMACEUTICALS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →